en
Scientific article
English

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing

Publication date2020
Abstract

Proton pump inhibitors (PPIs) are widely used for acid suppression in the treatment and prevention of many conditions, including gastroesophageal reflux disease, gastric and duodenal ulcers, erosive esophagitis, Helicobacter pylori infection, and pathological hypersecretory conditions. Most PPIs are metabolized primarily by cytochrome P450 2C19 (CYP2C19) into inactive metabolites, and CYP2C19 genotype has been linked to PPI exposure, efficacy, and adverse effects. We summarize the evidence from the literature and provide therapeutic recommendations for PPI prescribing based on CYP2C19 genotype (updates at www.cpicpgx.org). The potential benefits of using CYP2C19 genotype data to guide PPI therapy include (i) identifying patients with genotypes predictive of lower plasma exposure and prescribing them a higher dose that will increase the likelihood of efficacy, and (ii) identifying patients on chronic therapy with genotypes predictive of higher plasma exposure and prescribing them a decreased dose to minimize the risk of toxicity that is associated with long-term PPI use, particularly at higher plasma concentrations.

Funding
  • European Commission - UPGx grant 668353
Citation (ISO format)
LIMA, John J et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing. In: Clinical Pharmacology and Therapeutics, 2020. doi: 10.1002/cpt.2015
Main files (1)
Article (Published version)
accessLevelRestricted
Identifiers
ISSN of the journal0009-9236
165views
0downloads

Technical informations

Creation02/16/2021 3:49:00 PM
First validation02/16/2021 3:49:00 PM
Update time03/16/2023 12:19:38 AM
Status update03/16/2023 12:19:37 AM
Last indexation10/19/2023 3:02:35 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack